Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
You may also be interested in...
A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.
Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue.
The immuno-oncology developer optioned its BCMA-targeting drug to AbbVie for $50m upfront, while it plans to retain a focus on solid-tumor candidates.